Key result
Among patients undergoing rotational atherectomy, acute coronary syndrome presentation was associated with a higher 24-month risk of major cardiovascular events compared to stable disease.
Why the study?
Does rotational atherectomy in patients with acute coronary syndrome have similar feasibility, safety, and long-term outcomes compared to patients with stable coronary artery disease?
Observational (n=541)
No
Does rotational atherectomy in patients with acute coronary syndrome have similar feasibility, safety, and long-term outcomes compared to patients with stable coronary artery disease?
Answers are grounded in this paper and cite their sources.
Rotational atherectomy is feasible and safe in ACS patients with similar procedural success to SCAD patients, though long-term MACE remains significantly higher in the ACS population.
OBJECTIVES: We aimed to investigate the feasibility, safety, and outcome of rotational atherectomy (RA) in the setting of acute coronary syndrome (ACS). BACKGROUND: Limited data are available on the use of RA in patients presenting with ACS. METHODS: This analysis is from an observational registry, which enrolled all consecutive patients undergoing RA in a tertiary center. Between 2002 and 2015, 433 patients with stable coronary artery disease (SCAD) were treated with RA. Within the same period, 108 patients with ACS (8 STEMI and 100 NSTE-ACS) were treated with RA. Procedural success was similar between the ACS and the SCAD groups (96.6% vs. 96.4%, P = 0.90), and no significant difference was observed in procedural complications (slow-flow: 0.8% vs. 2.8%, P = 0.32; coronary dissection: 6.8% vs. 7.2%, P = 1.00; coronary perforation: 0.8% vs. 1.7%, P = 0.69). In-hospital MACE rates were comparable (3.7% vs. 3.2%, P = 0.77). The risk of MACE within 24 months was higher in ACS patients (39.9% vs. 22.4%, log-rank P = 0.002; HR: 1.39; 95% CI: 1.12-1.73; P = 0.003). Multivariable Cox regression analysis identified left ventricular ejection fraction (HR 0.97; 95% CI: 0.85-0.99; P = 0.001), treatment with a BMS (HR 2.22, 95% CI: 1.15-4.25, P = 0.02) or early generation drug eluting stent (HR 1.99; 95% CI 1.09-3.64; P = 0.03), as well as ACS presentation (HR 1.53; 95% CI: 1.02-2.29; P = 0.04) as predictors of MACE at two years. CONCLUSIONS: RA is technically feasible and safe in high risk patients presenting with ACS. However, successful application of RA did not mitigate the higher rate of long term cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Allali et al. (2018) conducted an observational in Acute coronary syndrome and stable coronary artery disease (n=541). Acute coronary syndrome presentation vs. Stable coronary artery disease was evaluated on MACE within 24 months (HR 1.39, 95% CI 1.12-1.73, p=0.003). Among patients undergoing rotational atherectomy, acute coronary syndrome presentation was associated with a higher 24-month risk of major cardiovascular events compared to stable disease.
Synapse has enriched 10 related papers. Consider them for comparative context: